Amir Saffarian, MD
Urology · Morgan Hill
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 16
- 2 carriers
- Office
- 1
Offices
1 location
Looking this up.
Hospitals listed: El Camino Health · Hazel Hawkins Memorial Hospital · Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
16 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Saffarian’s office at (408) 779-2009 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
16 of 16 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A65914 · Current
Licensed to practise in California · since 1998 · expires 2028-07-31 · Ohio State University College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Hazel Hawkins Memorial HospitalHollister, CACritical Access Hospital · Government - Hospital District or Authority · Has an emergency departmentNo overall ratingNo measure marked better or worse than the national rate
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Hazel Hawkins Memorial Hospital
Behind the star rating — Readmissions: 0 better, 2 the same, 0 worse of 2 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.6 to 17.1) · 409 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 43 cases | No different | Jan 2024 – Dec 2024 |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$1,130,957
Medicare paid this office $1,130,957 for 773 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 70 | $388,117 | $1,013 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 70 | $104,284 | $1,448 |
| Return visit (30+ min) | 446 | $77,775 | $115 |
| Unclassified drugs | 42 | $65,371 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 162 | $43,553 | $256 |
See all 34 services
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 70 | $388,117 | $1,013 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 70 | $104,284 | $1,448 |
| Return visit (30+ min) | 446 | $77,775 | $115 |
| Unclassified drugs | 42 | $65,371 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 162 | $43,553 | $256 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 29 | $43,514 | $870 |
| Leuprolide injectable, camcevi, 1 mg | 18 | $41,576 | None |
| Short return visit (20+ min) | 331 | $37,364 | $83 |
| New patient visit (45+ min) | 221 | $33,699 | $152 |
| Destruction of prostate tissue using radiofrequency induced heated water vapor | 16 | $28,187 | $1,762 |
| Botox | 26 | $25,913 | None |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 41 | $18,337 | $426 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 604 | $17,078 | $15 |
| Insertion of sacral nerve neurostimulator electrode array | 14 | $16,929 | $1,209 |
| Ultrasound scan of pelvic region through rectum | 89 | $15,913 | $158 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 26 | $15,390 | $416 |
| Placement of hormone pellet under skin | 43 | $11,655 | $86 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 12 | $10,583 | None |
| Insertion of device into abdomen with pressure and urine flow rate study | 40 | $9,120 | $217 |
| Short return visit | 147 | $8,742 | $52 |
| Simple bladder irrigation and/or instillation | 83 | $6,776 | $68 |
| Limited ultrasound scan of pelvis | 126 | $6,204 | $49 |
| Biopsy of prostate gland | 21 | $5,445 | $248 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 11 | $3,817 | $347 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 24 | $2,990 | $120 |
| Long return visit (40+ min) | 11 | $2,219 | $185 |
| Electronic assessment of bladder emptying | 146 | $2,099 | $12 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 41 | $1,461 | $34 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 24 | $1,364 | $37 |
| Ultrasonic guidance for needle placement | 17 | $1,051 | $62 |
| New patient visit (30+ min) | 11 | $1,034 | $94 |
| Ultrasound measurement of bladder capacity after voiding | 61 | $982 | $12 |
| Insertion of stent in ureter using an endoscope | 11 | $873 | $73 |
| Urinalysis, manual test | 22 | $222 | $3 |
Procedures Medicare counted
| Prostate resection | 39 | More than 94% of doctors who do this |
| Removal of skin lesions | 27 | More than 68% of doctors who do this |
Who their Medicare patients are
773 Original Medicare patients in 2024. Average age 75 · Under 65 4% · 85 and older 12% · Women 22% · Also on Medicaid 9% · Health risk score 1.14. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Diabetes 38% · Coronary heart disease 34% · Cancer 25% · Chronic kidney disease 22% · Atrial fibrillation 19% · Heart failure 17% · Depression 15% · COPD 12% · Dementia 8% · Stroke 7%.
The office billed $4,156,361, Medicare allowed $1,440,912 and paid $1,130,957; for 13,680 services of 76 kinds; $82,558 of it was for drugs given in the office and $1,048,400 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 773 | 13,680 | 75 | 1.14 | $4,156,361 | $1,130,957 |
| 2023 | 651 | 8,581 | 75 | 1.12 | $2,495,764 | $846,357 |
| 2022 | 631 | 7,675 | 75 | 1.09 | $2,733,920 | $1,023,827 |
| 2021 | 575 | 6,555 | 75 | 1.07 | $1,922,831 | $744,808 |
| 2020 | 497 | 4,797 | 75 | 1.15 | $1,748,278 | $589,503 |
| 2019 | 518 | 5,123 | 75 | 1.06 | $2,567,526 | $687,719 |
| 2018 | 531 | 4,682 | 75 | 1.19 | $1,513,294 | $514,872 |
| 2017 | 492 | 4,273 | 75 | 1.24 | $1,209,453 | $367,541 |
| 2016 | 434 | 4,349 | 75 | 1.36 | $1,210,627 | $352,992 |
| 2015 | 392 | 2,669 | 76 | 1.33 | $917,094 | $284,201 |
| 2014 | 358 | 2,291 | 75 | 1.17 | $849,489 | $254,500 |
| 2013 | 325 | 1,924 | 74 | 1.37 | $655,583 | $204,730 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 32 services
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 50 | $259,133 | $978 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 50 | $69,185 | $1,384 |
| Unclassified drugs | 43 | $56,210 | None |
| Injection of biodegradable material next to prostate | 15 | $48,640 | $3,243 |
| Return visit (30+ min) | 289 | $42,032 | $109 |
| Diagnostic exam of bladder and urethra using an endoscope | 153 | $39,839 | $239 |
| Short return visit (20+ min) | 315 | $34,500 | $77 |
| Destruction of prostate tissue using radiofrequency induced heated water vapor | 17 | $31,030 | $1,825 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 21 | $23,021 | None |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 20 | $21,767 | $837 |
| New patient visit (45+ min) | 152 | $21,285 | $140 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 48 | $20,153 | $403 |
| Botox | 15 | $16,258 | None |
| Insertion of sacral nerve neurostimulator electrode array | 11 | $12,809 | $1,164 |
| Insertion of device into abdomen with pressure and urine flow rate study | 48 | $10,507 | $210 |
| Ultrasound scan of pelvic region through rectum | 65 | $10,264 | $147 |
| Insertion of needle or tube into prostate for radiation therapy | 14 | $10,114 | $722 |
| Placement of hormone pellet under skin | 44 | $9,451 | $83 |
| New patient visit (60+ min) | 51 | $9,388 | $184 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 15 | $8,786 | $399 |
| Short return visit | 129 | $7,557 | $49 |
| Simple bladder irrigation and/or instillation | 84 | $6,892 | $70 |
| Limited ultrasound scan of pelvis | 122 | $5,908 | $48 |
| Long return visit (40+ min) | 17 | $3,793 | $172 |
| Biopsy of prostate gland | 14 | $3,419 | $244 |
| Electronic assessment of bladder emptying | 150 | $1,932 | $11 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 48 | $1,599 | $32 |
| Ultrasonic guidance for needle placement | 24 | $1,416 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,215 | $101 |
| Simple insertion of temporary bladder tube | 11 | $1,214 | $58 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $1,198 | $32 |
| Ultrasound measurement of bladder capacity after voiding | 59 | $774 | $11 |
2022: 34 services
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 77 | $365,423 | $1,021 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 77 | $113,042 | $1,449 |
| Injection of biodegradable material next to prostate | 17 | $54,927 | $3,231 |
| Unclassified drugs | 37 | $53,904 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 174 | $47,295 | $249 |
| Destruction of prostate tissue using radiofrequency induced heated water vapor | 22 | $42,076 | $1,913 |
| Return visit (30+ min) | 250 | $41,253 | $116 |
| Short return visit (20+ min) | 317 | $34,006 | $76 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 25 | $31,721 | None |
| New patient visit (45+ min) | 145 | $21,080 | $145 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 21 | $20,823 | $868 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 47 | $19,592 | $417 |
| Ultrasound scan of pelvic region through rectum | 86 | $14,230 | $150 |
| Botox | 14 | $14,206 | None |
| Insertion of sacral nerve neurostimulator electrode array | 11 | $13,064 | $1,188 |
| Insertion of needle or tube into prostate for radiation therapy | 17 | $11,771 | $692 |
| New patient visit (60+ min) | 62 | $11,362 | $183 |
| Short return visit | 170 | $10,324 | $50 |
| Insertion of device into abdomen with pressure and urine flow rate study | 46 | $10,092 | $219 |
| Simple bladder irrigation and/or instillation | 115 | $9,579 | $74 |
| Placement of hormone pellet under skin | 38 | $9,245 | $86 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 14 | $8,103 | $405 |
| Limited ultrasound scan of pelvis | 120 | $5,777 | $48 |
| Biopsy of prostate gland | 22 | $5,075 | $231 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 14 | $4,718 | $337 |
| Long return visit (40+ min) | 24 | $4,386 | $169 |
| Ultrasonic guidance for needle placement | 34 | $2,143 | $60 |
| Electronic assessment of bladder emptying | 144 | $1,835 | $11 |
| Simple insertion of temporary bladder tube | 16 | $1,735 | $64 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 47 | $1,553 | $33 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,480 | $114 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 25 | $1,479 | $32 |
| Ultrasound measurement of bladder capacity after voiding | 69 | $840 | $11 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 11 | $185 | $12 |
2021: 28 services
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 41 | $194,531 | $1,118 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 41 | $63,162 | $1,541 |
| Destruction of prostate tissue using radiofrequency induced heated water vapor | 31 | $62,381 | $2,012 |
| Unclassified drugs | 38 | $60,032 | None |
| Short return visit (20+ min) | 357 | $45,484 | $80 |
| Diagnostic exam of bladder and urethra using an endoscope | 152 | $38,624 | $233 |
| Return visit (30+ min) | 242 | $36,989 | $112 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 21 | $29,277 | $861 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 20 | $19,497 | None |
| New patient visit (45+ min) | 119 | $16,883 | $142 |
| New patient visit (60+ min) | 62 | $11,899 | $192 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 28 | $11,468 | $410 |
| Placement of hormone pellet under skin | 39 | $10,015 | $84 |
| Ultrasound scan of pelvic region through rectum | 56 | $8,803 | $147 |
| Simple bladder irrigation and/or instillation | 82 | $6,997 | $77 |
| Short return visit | 105 | $6,606 | $51 |
| Limited ultrasound scan of pelvis | 119 | $5,733 | $48 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 19 | $5,652 | $297 |
| Insertion of device into abdomen with pressure and urine flow rate study | 27 | $5,537 | $205 |
| Biopsy of prostate gland | 19 | $4,704 | $248 |
| Long return visit (40+ min) | 17 | $2,980 | $166 |
| Electronic assessment of bladder emptying | 166 | $2,363 | $12 |
| Ultrasonic guidance for needle placement | 39 | $2,323 | $58 |
| New patient visit (30+ min) | 16 | $1,635 | $102 |
| Ultrasound measurement of bladder capacity after voiding | 100 | $1,301 | $10 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 20 | $1,062 | $30 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 28 | $932 | $33 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 18 | $514 | $16 |
2020: 26 services
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 30 | $121,382 | $1,103 |
| Destruction of prostate tissue using radiofrequency induced heated water vapor | 46 | $86,475 | $1,880 |
| Unclassified drugs | 39 | $54,784 | None |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 30 | $43,578 | $1,453 |
| Short return visit (20+ min) | 312 | $34,109 | $67 |
| Return visit (30+ min) | 228 | $29,221 | $93 |
| Diagnostic exam of bladder and urethra using an endoscope | 119 | $27,881 | $210 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 19 | $27,001 | $794 |
| New patient visit (45+ min) | 105 | $14,305 | $136 |
| Ultrasound scan of pelvic region through rectum | 83 | $13,096 | $151 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $12,834 | None |
| New patient visit (60+ min) | 69 | $12,209 | $177 |
| Placement of hormone pellet under skin | 40 | $10,215 | $91 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 21 | $7,984 | $363 |
| Limited ultrasound scan of pelvis | 118 | $5,804 | $49 |
| Simple bladder irrigation and/or instillation | 71 | $5,482 | $70 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 14 | $3,990 | $285 |
| Insertion of device into abdomen with pressure and urine flow rate study | 21 | $3,831 | $174 |
| Biopsy of prostate gland | 15 | $3,808 | $254 |
| Electronic assessment of bladder emptying | 157 | $2,589 | $13 |
| Long return visit (40+ min) | 16 | $2,050 | $121 |
| Short return visit | 32 | $1,961 | $44 |
| Ultrasound measurement of bladder capacity after voiding | 77 | $1,124 | $10 |
| Ultrasonic guidance for needle placement | 15 | $930 | $58 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 20 | $709 | $34 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 12 | $256 | $18 |
2019: 29 services
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 36 | $207,503 | $1,032 |
| Unclassified drugs | 39 | $54,027 | None |
| Injection of biodegradable material next to prostate | 14 | $52,586 | $3,756 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 36 | $48,430 | $1,345 |
| Short return visit (20+ min) | 342 | $38,453 | $65 |
| Destruction of prostate tissue using radiofrequency induced heated water vapor | 16 | $31,048 | $1,941 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 26 | $28,385 | $728 |
| Return visit (30+ min) | 208 | $27,500 | $96 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 17 | $26,780 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 130 | $24,789 | $175 |
| New patient visit (60+ min) | 73 | $13,088 | $179 |
| Ultrasound scan of pelvic region through rectum | 85 | $12,847 | $132 |
| New patient visit (45+ min) | 86 | $11,991 | $139 |
| Insertion of needle or tube into prostate for radiation therapy | 13 | $9,253 | $712 |
| Placement of hormone pellet under skin | 40 | $8,885 | $88 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 24 | $8,386 | $349 |
| Long return visit (40+ min) | 40 | $5,778 | $123 |
| Simple bladder irrigation and/or instillation | 73 | $5,391 | $62 |
| Limited ultrasound scan of pelvis | 102 | $4,890 | $48 |
| Biopsy of prostate gland | 18 | $4,457 | $248 |
| Insertion of device into abdomen with pressure and urine flow rate study | 24 | $3,458 | $144 |
| Electronic assessment of bladder emptying | 175 | $2,540 | $12 |
| Short return visit | 36 | $1,809 | $40 |
| Electronic analysis of implanted neurostimulator generator with simple spinal cord or peripheral nerve stimulator programming | 17 | $1,137 | $45 |
| Ultrasound measurement of bladder capacity after voiding | 67 | $1,006 | $12 |
| Ultrasonic guidance for needle placement | 17 | $948 | $56 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $922 | $29 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 24 | $800 | $33 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 11 | $714 | $48 |
2018: 28 services
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 20 | $101,367 | $1,034 |
| Unclassified drugs | 34 | $43,672 | None |
| Short return visit (20+ min) | 366 | $40,371 | $61 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 27 | $30,183 | $719 |
| Return visit (30+ min) | 204 | $28,297 | $93 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 20 | $26,234 | $1,312 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $19,829 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 120 | $19,435 | $153 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 43 | $15,307 | $348 |
| New patient visit (45+ min) | 98 | $14,400 | $147 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 16 | $10,492 | $656 |
| New patient visit (60+ min) | 58 | $9,351 | $161 |
| Placement of hormone pellet under skin | 34 | $7,946 | $85 |
| Long return visit (40+ min) | 46 | $5,723 | $117 |
| Limited ultrasound scan of pelvis | 117 | $5,491 | $47 |
| Insertion of device into abdomen with pressure and urine flow rate study | 43 | $5,095 | $116 |
| Ultrasound scan of pelvic region through rectum | 45 | $4,471 | $95 |
| Biopsy of prostate gland | 19 | $4,246 | $223 |
| Electronic assessment of bladder emptying | 224 | $4,152 | $13 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 25 | $3,317 | $66 |
| Ultrasound measurement of bladder capacity after voiding | 101 | $2,197 | $15 |
| Short return visit | 48 | $2,005 | $36 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 25 | $1,832 | $56 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 43 | $1,496 | $34 |
| Simple bladder irrigation and/or instillation | 18 | $967 | $51 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $712 | $27 |
| Urinalysis, manual test | 18 | $310 | $3 |
| Imaging of urinary tract following injection of a contrast agent | 13 | $257 | $16 |
2017: 28 services
| Short return visit (20+ min) | 374 | $44,863 | $58 |
| Unclassified drugs | 20 | $31,323 | None |
| Destruction of prostate tissue using radiofrequency induced heat | 13 | $24,264 | $1,866 |
| Return visit (30+ min) | 149 | $18,873 | $90 |
| Diagnostic exam of bladder and urethra using an endoscope | 113 | $17,594 | $149 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $17,180 | None |
| New patient visit (45+ min) | 127 | $16,514 | $130 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 21 | $15,830 | $660 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 20 | $14,785 | $739 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 42 | $14,154 | $329 |
| New patient visit (60+ min) | 48 | $7,873 | $164 |
| Limited ultrasound scan of pelvis | 136 | $6,040 | $44 |
| Biopsy of prostate gland | 26 | $5,482 | $211 |
| Placement of hormone pellet under skin | 21 | $4,947 | $75 |
| Insertion of device into abdomen with pressure and urine flow rate study | 42 | $4,669 | $109 |
| Ultrasound scan of pelvic region through rectum | 45 | $4,364 | $91 |
| Long return visit (40+ min) | 32 | $4,204 | $124 |
| Electronic assessment of bladder emptying | 221 | $4,129 | $13 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 23 | $3,575 | $62 |
| Short return visit | 74 | $3,434 | $39 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 15 | $3,381 | $225 |
| Ultrasound measurement of bladder capacity after voiding | 127 | $3,273 | $18 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 42 | $1,392 | $32 |
| Simple insertion of temporary bladder tube | 13 | $964 | $57 |
| Insertion of temporary bladder tube | 17 | $920 | $44 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $634 | $28 |
| Imaging of urinary tract following injection of a contrast agent | 14 | $293 | $15 |
| Urinalysis, manual test | 13 | $172 | $3 |
2016: 33 services
| Short return visit (20+ min) | 321 | $39,661 | $62 |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 11 | $32,115 | $1,004 |
| Unclassified drugs | 27 | $31,774 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 107 | $21,082 | $183 |
| Destruction of prostate tissue using radiofrequency induced heat | 11 | $19,764 | $1,797 |
| Return visit (30+ min) | 154 | $19,660 | $88 |
| New patient visit (45+ min) | 120 | $16,304 | $136 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 12 | $16,003 | None |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 45 | $15,399 | $335 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 11 | $13,967 | $1,270 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 16 | $11,797 | $737 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 12 | $10,753 | $672 |
| Placement of hormone pellet under skin | 28 | $5,743 | $75 |
| Botox | 11 | $5,489 | None |
| Limited ultrasound scan of pelvis | 114 | $5,239 | $46 |
| Insertion of device into abdomen with pressure and urine flow rate study | 45 | $5,060 | $110 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 19 | $4,456 | $223 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 45 | $4,310 | $94 |
| New patient visit (60+ min) | 26 | $4,252 | $164 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 11 | $3,915 | $301 |
| Electronic assessment of bladder emptying | 181 | $3,601 | $13 |
| Ultrasound scan of pelvic region through rectum | 35 | $3,433 | $93 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 20 | $2,875 | $65 |
| Ultrasound measurement of bladder capacity after voiding | 106 | $2,845 | $18 |
| Biopsy of prostate gland | 13 | $2,440 | $188 |
| Long return visit (40+ min) | 17 | $2,293 | $127 |
| Ultrasonic guidance for needle placement | 33 | $2,026 | $58 |
| Insertion of stent in ureter using an endoscope | 16 | $1,478 | $78 |
| Short return visit | 32 | $999 | $29 |
| Insertion of temporary bladder tube | 12 | $694 | $53 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $679 | $28 |
| Simple bladder irrigation and/or instillation | 12 | $602 | $43 |
| Imaging of urinary tract following injection of a contrast agent | 16 | $309 | $15 |
2015: 27 services
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 12 | $28,576 | $985 |
| Return visit (30+ min) | 199 | $27,029 | $91 |
| Short return visit (20+ min) | 215 | $25,017 | $63 |
| Diagnostic exam of bladder and urethra using an endoscope | 100 | $20,342 | $190 |
| Unclassified drugs | 20 | $17,537 | None |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 12 | $15,105 | $1,259 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 39 | $13,257 | $331 |
| New patient visit (45+ min) | 94 | $13,178 | $140 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 14 | $10,142 | $724 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 11 | $9,476 | $677 |
| New patient visit (60+ min) | 37 | $6,671 | $180 |
| Insertion of device into abdomen with pressure and urine flow rate study | 38 | $4,303 | $110 |
| Limited ultrasound scan of pelvis | 94 | $4,253 | $45 |
| Placement of hormone pellet under skin | 20 | $3,834 | $87 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 39 | $3,762 | $94 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 14 | $3,433 | $229 |
| Electronic assessment of bladder emptying | 173 | $3,189 | $13 |
| Ultrasound measurement of bladder capacity after voiding | 127 | $3,082 | $18 |
| Long return visit (40+ min) | 17 | $2,017 | $119 |
| Ultrasound scan of pelvic region through rectum | 21 | $1,949 | $93 |
| Short return visit | 42 | $1,887 | $41 |
| Simple insertion of temporary bladder tube | 19 | $1,723 | $69 |
| Ultrasonic guidance for needle placement | 21 | $1,204 | $57 |
| Insertion of stent in ureter using an endoscope | 12 | $906 | $60 |
| Simple repair of surface wound of scalp, neck, underarms, trunk, arms, or legs, 2.5 cm or less | 12 | $810 | $43 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $617 | $34 |
| Imaging of urinary tract following injection of a contrast agent | 12 | $255 | $16 |
2014: 24 services
| Return visit (30+ min) | 194 | $27,963 | $95 |
| Destruction of prostate tissue using radiofrequency induced heat | 14 | $26,396 | $1,885 |
| Short return visit (20+ min) | 222 | $21,645 | $60 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 21 | $20,256 | $675 |
| Diagnostic exam of bladder and urethra using an endoscope | 87 | $16,807 | $185 |
| Unclassified drugs | 17 | $16,267 | None |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 43 | $14,128 | $329 |
| New patient visit (45+ min) | 88 | $12,487 | $142 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 13 | $9,734 | $749 |
| Limited ultrasound scan of pelvis | 114 | $6,002 | $52 |
| New patient visit (60+ min) | 28 | $5,257 | $188 |
| Insertion of device into abdomen with pressure and urine flow rate study | 43 | $4,684 | $109 |
| Ultrasound measurement of bladder capacity after voiding | 156 | $4,619 | $18 |
| Electronic assessment of bladder emptying | 225 | $4,603 | $13 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 43 | $4,041 | $94 |
| Placement of hormone pellet under skin | 17 | $3,191 | $91 |
| Long return visit (40+ min) | 22 | $2,917 | $122 |
| Ultrasound scan of pelvic region through rectum | 26 | $2,405 | $92 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 11 | $1,829 | $102 |
| Ultrasonic guidance for needle placement | 24 | $1,726 | $72 |
| Simple repair of surface wound of scalp, neck, underarms, trunk, arms, or legs, 2.5 cm or less | 17 | $1,457 | $43 |
| Insertion of temporary bladder tube | 18 | $1,426 | $53 |
| Simple insertion of temporary bladder tube | 11 | $1,021 | $68 |
| Electronic analysis of implanted neurostimulator generator with simple spinal cord or peripheral nerve stimulator programming | 11 | $781 | $56 |
2013: 20 services
| Short return visit (20+ min) | 215 | $26,754 | $62 |
| Unclassified drugs | 14 | $14,272 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 69 | $13,787 | $186 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 12 | $12,993 | $684 |
| Return visit (30+ min) | 108 | $12,342 | $90 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 29 | $9,959 | $343 |
| New patient visit (60+ min) | 54 | $9,407 | $174 |
| Limited ultrasound scan of pelvis | 106 | $8,980 | $83 |
| New patient visit (45+ min) | 63 | $8,750 | $139 |
| Electronic assessment of bladder emptying | 198 | $3,973 | $13 |
| Ultrasound measurement of bladder capacity after voiding | 138 | $3,631 | $19 |
| Insertion of device into abdomen with pressure and urine flow rate study | 29 | $3,276 | $113 |
| Ultrasonic guidance for needle placement | 13 | $2,902 | $207 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 29 | $2,781 | $96 |
| Placement of hormone pellet under skin | 14 | $2,294 | $92 |
| Long return visit (40+ min) | 16 | $2,266 | $126 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 17 | $1,754 | $70 |
| Simple repair of surface wound of scalp, neck, underarms, trunk, arms, or legs, 2.5 cm or less | 14 | $1,104 | $44 |
| Insertion of temporary bladder tube | 12 | $1,011 | $53 |
| Ultrasound scan of pelvic region through rectum | 13 | $1,001 | $71 |
Drugs they prescribed that Part D paid
$112,225
Pharmacies billed $112,225 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (58 of 2,436) in 2024. Above the middle of the specialty; the typical urology clinician is at 2%.
2,276 generic and 160 brand-name prescriptions · $112,225 in drug cost · 726 antibiotic prescriptions to 365 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 60 | $54,884 | $915 |
| Gemtesa | 15 | $16,756 | $1,117 |
| Tamsulosin | 714 | $10,776 | $15 |
| Oxybutynin Chloride Er | 240 | $7,470 | $31 |
| Finasteride | 427 | $5,476 | $13 |
See all 17 drugs
| Myrbetriq | 60 | $54,884 | $915 |
| Gemtesa | 15 | $16,756 | $1,117 |
| Tamsulosin | 714 | $10,776 | $15 |
| Oxybutynin Chloride Er | 240 | $7,470 | $31 |
| Finasteride | 427 | $5,476 | $13 |
| Nitrofurantoin | 92 | $4,331 | $47 |
| Solifenacin | 51 | $2,378 | $47 |
| Testosterone | 29 | $2,261 | $78 |
| Bicalutamide | 49 | $1,744 | $36 |
| Nitrofurantoin Mono-Macro | 320 | $1,633 | $5 |
| Testosterone Cypionate | 15 | $868 | $58 |
| Potassium Citrate Er | 12 | $715 | $60 |
| Amoxicillin-Clavulanate Potass | 156 | $675 | $4 |
| Hydrocodone-Acetaminophen | 52 | $505 | $10 |
| Ciprofloxacin | 66 | $329 | $5 |
| Cephalexin | 47 | $308 | $7 |
| Sulfamethoxazole-Trimethoprim | 42 | $235 | $6 |
Year by year
| 2024 | 2,436 | 649 | 2% (58) | 7% | $112,225 |
| 2023 | 2,052 | 562 | 3% (60) | 8% | $105,383 |
| 2022 | 2,030 | 509 | 8% (170) | None | $75,821 |
| 2021 | 1,916 | 461 | 7% (135) | 5% | $55,846 |
| 2020 | 1,556 | 395 | 6% (95) | 6% | $67,049 |
| 2019 | 1,376 | 374 | 6% (84) | 6% | $64,421 |
| 2018 | 1,362 | 365 | 4% (54) | 12% | $84,932 |
| 2017 | 1,290 | 331 | 4% (46) | None | $81,009 |
| 2016 | 1,098 | 280 | 4% (45) | None | $76,528 |
| 2015 | 970 | 263 | 3% (32) | 16% | $80,194 |
| 2014 | 1,003 | 230 | 3% (34) | 18% | $75,010 |
| 2013 | 841 | 189 | 2% (20) | 18% | $60,535 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Myrbetriq | 40 | $51,882 | $1,297 |
| Tamsulosin | 570 | $12,637 | $22 |
| Oxybutynin Chloride Er | 208 | $11,276 | $54 |
| Nitrofurantoin | 72 | $6,430 | $89 |
| Solifenacin | 37 | $6,278 | $170 |
| Finasteride | 330 | $5,768 | $17 |
| Bicalutamide | 46 | $3,571 | $78 |
| Nitrofurantoin Mono-Macro | 312 | $1,781 | $6 |
| Testosterone | 31 | $1,590 | $51 |
| Amoxicillin-Clavulanate Potass | 142 | $786 | $6 |
| Hydrocodone-Acetaminophen | 56 | $492 | $9 |
| Ciprofloxacin | 68 | $394 | $6 |
| Cephalexin | 53 | $260 | $5 |
| Sulfamethoxazole-Trimethoprim | 30 | $126 | $4 |
2022: 14 drugs
| Myrbetriq | 23 | $31,099 | $1,352 |
| Oxybutynin Chloride Er | 233 | $15,743 | $68 |
| Tamsulosin | 439 | $8,739 | $20 |
| Nitrofurantoin | 41 | $4,423 | $108 |
| Finasteride | 236 | $4,179 | $18 |
| Nitrofurantoin Mono-Macro | 295 | $2,096 | $7 |
| Bicalutamide | 43 | $2,021 | $47 |
| Testosterone | 24 | $1,706 | $71 |
| Amoxicillin-Clavulanate Potass | 121 | $613 | $5 |
| Hydrocodone-Acetaminophen | 167 | $578 | $3 |
| Cephalexin | 87 | $556 | $6 |
| Sulfamethoxazole-Trimethoprim | 94 | $341 | $4 |
| Ciprofloxacin | 42 | $303 | $7 |
| Lorazepam | 117 | $99 | $1 |
2021: 15 drugs
| Myrbetriq | 20 | $19,458 | $973 |
| Oxybutynin Chloride Er | 246 | $11,337 | $46 |
| Tamsulosin | 473 | $8,398 | $18 |
| Finasteride | 260 | $5,099 | $20 |
| Testosterone | 19 | $2,292 | $121 |
| Nitrofurantoin | 23 | $2,129 | $93 |
| Bicalutamide | 35 | $1,570 | $45 |
| Nitrofurantoin Mono-Macro | 226 | $1,492 | $7 |
| Testosterone Cypionate | 12 | $576 | $48 |
| Cephalexin | 105 | $500 | $5 |
| Hydrocodone-Acetaminophen | 135 | $492 | $4 |
| Sulfamethoxazole-Trimethoprim | 136 | $397 | $3 |
| Amoxicillin-Clavulanate Potass | 57 | $350 | $6 |
| Ciprofloxacin | 47 | $312 | $7 |
| Lorazepam | 92 | $83 | $1 |
2020: 13 drugs
| Myrbetriq | 28 | $24,159 | $863 |
| Oxybutynin Chloride Er | 252 | $13,916 | $55 |
| Tamsulosin | 373 | $7,108 | $19 |
| Finasteride | 266 | $5,667 | $21 |
| Testosterone | 23 | $5,442 | $237 |
| Nitrofurantoin | 35 | $3,224 | $92 |
| Nitrofurantoin Mono-Macro | 98 | $1,375 | $14 |
| Bicalutamide | 13 | $913 | $70 |
| Cephalexin | 129 | $442 | $3 |
| Sulfamethoxazole-Trimethoprim | 111 | $396 | $4 |
| Hydrocodone-Acetaminophen | 93 | $307 | $3 |
| Ciprofloxacin | 31 | $204 | $7 |
| Lorazepam | 58 | $62 | $1 |
2019: 13 drugs
| Myrbetriq | 19 | $15,612 | $822 |
| Oxybutynin Chloride Er | 206 | $14,206 | $69 |
| Tamsulosin | 314 | $7,041 | $22 |
| Testosterone | 20 | $6,873 | $344 |
| Finasteride | 226 | $5,870 | $26 |
| Nitrofurantoin | 17 | $1,859 | $109 |
| Cephalexin | 205 | $656 | $3 |
| Bicalutamide | 16 | $573 | $36 |
| Sulfamethoxazole-Trimethoprim | 131 | $432 | $3 |
| Nitrofurantoin Mono-Macro | 30 | $335 | $11 |
| Hydrocodone-Acetaminophen | 83 | $290 | $3 |
| Ciprofloxacin | 17 | $126 | $7 |
| Lorazepam | 53 | $63 | $1 |
2018: 14 drugs
| Myrbetriq | 29 | $22,583 | $779 |
| Androgel | 24 | $15,313 | $638 |
| Oxybutynin Chloride Er | 169 | $13,098 | $78 |
| Tamsulosin | 340 | $10,115 | $30 |
| Finasteride | 220 | $6,025 | $27 |
| Nitrofurantoin | 46 | $3,873 | $84 |
| Bicalutamide | 23 | $831 | $36 |
| Nitrofurantoin Mono-Macro | 104 | $781 | $8 |
| Cephalexin | 139 | $660 | $5 |
| Ciprofloxacin | 60 | $416 | $7 |
| Sulfamethoxazole-Trimethoprim | 61 | $256 | $4 |
| Hydrocodone-Acetaminophen | 53 | $243 | $5 |
| Amoxicillin-Clavulanate Potass | 16 | $157 | $10 |
| Lorazepam | 27 | $45 | $2 |
2017: 15 drugs
| Myrbetriq | 47 | $26,136 | $556 |
| Androgel | 24 | $13,271 | $553 |
| Tamsulosin | 316 | $9,715 | $31 |
| Oxybutynin Chloride Er | 123 | $9,356 | $76 |
| Finasteride | 215 | $4,915 | $23 |
| Nitrofurantoin | 31 | $2,845 | $92 |
| Potassium Citrate Er | 17 | $2,687 | $158 |
| Nitrofurantoin Mono-Macro | 148 | $1,345 | $9 |
| Bicalutamide | 18 | $591 | $33 |
| Cephalexin | 111 | $525 | $5 |
| Bethanechol Chloride | 12 | $471 | $39 |
| Sulfamethoxazole-Trimethoprim | 87 | $455 | $5 |
| Ciprofloxacin | 47 | $278 | $6 |
| Hydrocodone-Acetaminophen | 42 | $208 | $5 |
| Lorazepam | 15 | $22 | $1 |
2016: 15 drugs
| Myrbetriq | 33 | $21,224 | $643 |
| Androgel | 25 | $13,681 | $547 |
| Vesicare | 15 | $11,540 | $769 |
| Tamsulosin | 274 | $8,370 | $31 |
| Oxybutynin Chloride Er | 101 | $5,958 | $59 |
| Finasteride | 172 | $3,802 | $22 |
| Nitrofurantoin | 37 | $3,359 | $91 |
| Nitrofurantoin Mono-Macro | 101 | $1,819 | $18 |
| Bethanechol Chloride | 12 | $552 | $46 |
| Bicalutamide | 19 | $524 | $28 |
| Ciprofloxacin | 122 | $485 | $4 |
| Sulfamethoxazole-Trimethoprim | 46 | $361 | $8 |
| Hydrocodone-Acetaminophen | 38 | $256 | $7 |
| Cephalexin | 38 | $205 | $5 |
| Lorazepam | 19 | $42 | $2 |
2015: 14 drugs
| Vesicare | 40 | $19,300 | $483 |
| Myrbetriq | 33 | $17,932 | $543 |
| Androgel | 28 | $12,834 | $458 |
| Tamsulosin | 228 | $9,108 | $40 |
| Oxybutynin Chloride Er | 89 | $7,687 | $86 |
| Finasteride | 182 | $3,273 | $18 |
| Nitrofurantoin | 35 | $2,063 | $59 |
| Nitrofurantoin Mono-Macro | 33 | $668 | $20 |
| Bethanechol Chloride | 12 | $634 | $53 |
| Ciprofloxacin | 174 | $626 | $4 |
| Bicalutamide | 13 | $474 | $36 |
| Hydrocodone-Acetaminophen | 24 | $148 | $6 |
| Cephalexin | 17 | $62 | $4 |
| Sulfamethoxazole-Trimethoprim | 15 | $49 | $3 |
2014: 16 drugs
| Vesicare | 70 | $23,220 | $332 |
| Androgel | 24 | $9,667 | $403 |
| Oxybutynin Chloride Er | 86 | $6,799 | $79 |
| Tamsulosin | 252 | $5,942 | $24 |
| Myrbetriq | 13 | $5,334 | $410 |
| Finasteride | 173 | $3,340 | $19 |
| Enablex | 13 | $2,741 | $211 |
| Nitrofurantoin | 36 | $2,641 | $73 |
| Nitrofurantoin Mono-Macro | 19 | $848 | $45 |
| Ciprofloxacin | 173 | $668 | $4 |
| Bicalutamide | 16 | $625 | $39 |
| Hydrocodone-Acetaminophen | 28 | $211 | $8 |
| Bethanechol Chloride | 12 | $177 | $15 |
| Sulfamethoxazole-Trimethoprim | 20 | $135 | $7 |
| Cephalexin | 13 | $71 | $5 |
| Lorazepam | 12 | $31 | $3 |
2013: 13 drugs
| Vesicare | 74 | $18,932 | $256 |
| Androgel | 22 | $8,487 | $386 |
| Oxybutynin Chloride Er | 97 | $6,931 | $71 |
| Testim | 15 | $5,379 | $359 |
| Tamsulosin | 208 | $4,538 | $22 |
| Nitrofurantoin | 42 | $4,079 | $97 |
| Finasteride | 121 | $3,506 | $29 |
| Bicalutamide | 24 | $1,116 | $47 |
| Nitrofurantoin Mono-Macro | 14 | $861 | $62 |
| Ciprofloxacin | 121 | $539 | $4 |
| Sulfamethoxazole-Trimethoprim | 19 | $176 | $9 |
| Terazosin | 17 | $143 | $8 |
| Hydrocodone-Acetaminophen | 17 | $66 | $4 |
Money from drug and device companies
$9,145 in 2025
| 2025 | 9 | 50 | $5,390 | $9,145 |
| 2024 | 10 | 49 | None | $4,160 |
| 2023 | 11 | 41 | None | $1,382 |
| 2022 | 15 | 44 | None | $2,490 |
| 2021 | 11 | 42 | None | $1,493 |
| 2020 | 10 | 28 | None | $1,550 |
| 2019 | 9 | 45 | None | $782 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Teleflex | Urolift | $8,063 | 14 payments
|
| Ferring Pharmaceuticals | Adstiladrin | $298 | 11 payments
|
| Accord Healthcare | Camcevi | $251 | 11 payments
|
| Abbvie | Botox | $188 | 6 payments
|
| Janssen Biotech | Rybrevant | $138 | 3 payments
|
| Sumitomo Pharma America | Gemtesa | $83 | 2 payments
|
See all 50 published payments
| Ferring Pharmaceuticals | Meals · 2025-12-16 | Adstiladrin | $15 |
| Teleflex | Meals · 2025-12-10 | Barrigel | $55 |
| Accord Healthcare | Meals · 2025-12-09 | Camcevi | $18 |
| Teleflex | Paid to speak or teach · 2025-12-05 | Urolift | $1,210 |
| Teleflex | Paid to speak or teach · 2025-12-05 | Urolift | $1,980 |
| Accord Healthcare | Meals · 2025-11-24 | Camcevi | $9 |
| Abbvie | Meals · 2025-11-18 | Botox | $33 |
| Teleflex | Meals · 2025-11-13 | Urolift | $169 |
| Accord Healthcare | Meals · 2025-10-30 | Camcevi | $11 |
| Ferring Pharmaceuticals | Meals · 2025-10-23 | Adstiladrin | $7 |
| Janssen Biotech | Meals · 2025-10-22 | Rybrevant | $125 |
| Teleflex | Meals · 2025-10-14 | Barrigel | $53 |
| Teleflex | Paid to speak or teach · 2025-10-03 | Urolift | $1,760 |
| Sumitomo Pharma America | Meals · 2025-09-30 | Gemtesa | $39 |
| Teleflex | Consulting · 2025-09-26 | Urolift | $440 |
| Janssen Biotech | Meals · 2025-09-25 | Erleada | $6 |
| Teleflex | Meals · 2025-09-22 | Urolift | $113 |
| Ferring Pharmaceuticals | Meals · 2025-09-19 | Adstiladrin | $6 |
| Olympus America | Meals · 2025-09-09 | Itind System | $44 |
| Sumitomo Pharma America | Meals · 2025-09-04 | Gemtesa | $43 |
| Accord Healthcare | Meals · 2025-08-30 | Camcevi | $9 |
| Abbvie | Meals · 2025-08-27 | Botox | $34 |
| Janssen Biotech | Meals · 2025-08-21 | Erleada | $8 |
| Teleflex | Meals · 2025-08-09 | Barrigel | $392 |
| Teleflex | Travel · 2025-08-09 | Barrigel | $946 |
| Abbvie | Meals · 2025-08-07 | Lupron Depot | $30 |
| Accord Healthcare | Meals · 2025-08-06 | Camcevi | $22 |
| Teleflex | Meals · 2025-07-15 | Urolift | $43 |
| Accord Healthcare | Meals · 2025-07-15 | Camcevi | $13 |
| Ferring Pharmaceuticals | Meals · 2025-07-09 | Adstiladrin | $32 |
| Ferring Pharmaceuticals | Meals · 2025-06-10 | Adstiladrin | $36 |
| Accord Healthcare | Meals · 2025-06-10 | Camcevi | $9 |
| Teleflex | Meals · 2025-05-23 | Barrigel | $60 |
| Teleflex | Meals · 2025-05-19 | Barrigel | $139 |
| Accord Healthcare | Meals · 2025-05-16 | Camcevi | $18 |
| Ferring Pharmaceuticals | Meals · 2025-05-14 | Adstiladrin | $9 |
| Abbvie | Meals · 2025-05-13 | Botox | $31 |
| Pfizer | Meals · 2025-05-06 | Xtandi | $37 |
| Ferring Pharmaceuticals | Meals · 2025-05-02 | Adstiladrin | $8 |
| Teleflex | Travel · 2025-05-02 | Urolift | $705 |
| Ferring Pharmaceuticals | Meals · 2025-04-26 | Adstiladrin | $103 |
| Accord Healthcare | Meals · 2025-04-25 | Camcevi | $126 |
| Ferring Pharmaceuticals | Meals · 2025-04-17 | Adstiladrin | $30 |
| Abbvie | Meals · 2025-04-15 | Lupron Depot | $28 |
| Accord Healthcare | Meals · 2025-04-09 | Camcevi | $7 |
| Abbvie | Meals · 2025-03-04 | Botox | $31 |
| Ferring Pharmaceuticals | Meals · 2025-03-03 | Adstiladrin | $44 |
| Accord Healthcare | Meals · 2025-02-26 | Camcevi | $8 |
| Agiliti Surgical | Meals · 2025-02-04 | Koelis Trinity Mri/US Fusion | $44 |
| Ferring Pharmaceuticals | Meals · 2025-02-04 | Adstiladrin | $7 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $4,160
| Teleflex | Urolift | $1,639 | 17 payments
|
| Axonics | Axonics | $1,072 | 4 payments
|
| PROCEPT BioRobotics | Aquabeam System | $933 | 6 payments
|
| Abbvie | Lupron Depot | $188 | 6 payments
|
| Accord Healthcare | Camcevi | $93 | 4 payments
|
| Medtronic | Interstim | $64 | 1 payment
|
| Boston Scientific | Rezum Generator | $55 | 2 payments
|
| Janssen Biotech | Erleada | $54 | 2 payments
|
| Endo Pharmaceuticals | Xiaflex | $46 | 2 payments
|
| Endo USA | Aveed | $18 | 1 payment
|
2023: $1,382
| Teleflex | Urolift | $366 | 6 payments
|
| Astellas Pharma US | Myrbetriq | $248 | 9 payments
|
| Axonics | Axonics | $242 | 3 payments
|
| Endo Pharmaceuticals | Aveed | $179 | 8 payments
|
| AbbVie | Botox | $154 | 8 payments
|
| Boston Scientific | Rezum Generator | $39 | 1 payment
|
| Janssen Biotech | Erleada | $38 | 1 payment
|
| AngioDynamics | Nanoknife | $34 | 1 payment
|
| Accord Healthcare | Camcevi | $31 | 2 payments
|
| UroGen Pharma | Jelmyto | $27 | 1 payment
|
| 180 Medical | Gentlecath | $24 | 1 payment
|
2022: $2,490
| Teleflex | Urolift | $1,486 | 10 payments
|
| Endo Pharmaceuticals | Aveed | $191 | 8 payments
|
| Olympus America | Itind System | $143 | 2 payments
|
| Astellas Pharma US | Myrbetriq | $132 | 4 payments
|
| Axonics | Axonics | $120 | 3 payments
|
| Boston Scientific | Rezum Generator | $76 | 3 payments
|
| Abbvie | Botox | $64 | 3 payments
|
| UroGen Pharma | Jelmyto | $49 | 2 payments
|
| Antares Pharma | Nocdurna | $44 | 1 payment
|
| Palette Life Sciences | None | $38 | 1 payment
|
| AngioDynamics | Nanoknife | $36 | 1 payment
|
| Urovant Sciences | Gemtesa | $34 | 1 payment
|
| Profound Medical | Tulsa-Pro | $28 | 1 payment
|
| Medtronic | Interstim | $27 | 1 payment
|
| Allergan | Botox | $21 | 1 payment
|
2021: $1,493
| Teleflex | Urolift System | $735 | 10 payments
|
| Astellas Pharma US | Myrbetriq | $199 | 5 payments
|
| AbbVie | Lupron Depot | $119 | 6 payments
|
| Allergan | Botox | $115 | 7 payments
|
| Boston Scientific | General Bph | $107 | 5 payments
|
| Endo Pharmaceuticals | Xiaflex | $66 | 3 payments
|
| Janssen Biotech | Erleada | $52 | 2 payments
|
| Urovant Sciences | Gemtesa | $36 | 1 payment
|
| Medtronic | Interstim | $26 | 1 payment
|
| Urogen Pharma | Jelmyto | $23 | 1 payment
|
| SRS Medical Systems | Urocuff | $15 | 1 payment
|
2020: $1,550
| NeoTract | Urolift | $1,053 | 6 payments
|
| Boston Scientific | General - Female Sui | $163 | 6 payments
|
| Astellas Pharma US | Myrbetriq | $68 | 3 payments
|
| Endo Pharmaceuticals | Xiaflex | $67 | 3 payments
|
| Janssen Biotech | Erleada | $50 | 2 payments
|
| AbbVie | Lupron Depot | $43 | 2 payments
|
| Axonics Modulation Technologies | Axonics R-Snm System | $33 | 2 payments
|
| Pfizer | Toviaz | $31 | 2 payments
|
| Allergan | Botox | $24 | 1 payment
|
| Medtronic USA | Interstim Icon | $17 | 1 payment
|
2019: $782
| NeoTract | Urolift | $208 | 4 payments
|
| Boston Scientific | General Bph | $186 | 18 payments
|
| Medtronic USA | Interstim Icon | $176 | 5 payments
|
| Janssen Biotech | Erleada | $133 | 13 payments
|
| Allergan | Botox | $21 | 1 payment
|
| AbbVie | Lupron Depot | $18 | 1 payment
|
| Zyla Life Sciences | Sprix | $15 | 1 payment
|
| Endo Pharmaceuticals | Aveed | $15 | 1 payment
|
| Pfizer | Eliquis | $12 | 1 payment
|
Checkups this office reported
10 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 87.7 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Advance care plan on fileOlder patients with an advance care plan or a documented conversation about one | 98%That's most of the people this applied to. | 971 |
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 99%That's most of the people this applied to. | 854 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 29%That's less than half. | 643 |
| Checked for fall riskOlder patients screened for fall risk | 68%That's more than half. | 930 |
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 67%That's more than half. | 1,638 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 93%That's most of the people this applied to. Worse on this measure. | 30 |
| Medications listed in the chartVisits where the current medication list was documented | 98%That's most of the people this applied to. | 3,139 |
| Risky medications in older adultsOlder patients given a medication that is risky at their age | 4%That's few of the people this applied to. Better on this measure. | 979 |
See the other 2 measures
| Screening for High Blood Pressure and Follow-Up DocumentedAs Medicare defines this measure | 9% | 1,679 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 79%That's most of the people this applied to. | 85 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Depression screening
- Implementation of fall screening and assessment programs
- Implementation of medication management practice improvements
- Improved the patient portal
- Lets patients read their visit notes
- Measurement and improvement at the practice and panel level
- Uses standard treatment protocols
Professional record
- NPI
- 1861590176
- Licence
- CA A65914California A65914: Current · expires 2028-07-31
- Trained
- Ohio State University College of Medicine, 1996
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 18181 Butterfield Blvd, Suite 185, Morgan Hill, CA, 95037
- NPI first listed
- 2006-09-20
- NPI last updated
- 2022-02-28
- NPI record certified
- 2022-02-28
This is when the NPI record was last certified, not a medical board exam.